# Lenvatinib Plus PD-1 Inhibitor for Advanced Solid Tumors With 11q13 Amplification

> **NCT07417501** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Tongji Hospital** · enrollment: 60 (estimated)

## Conditions studied

- Solid Tumors

## Interventions

- **DRUG:** Lenvatinib plus PD-1 Inhibitor

## Key facts

- **NCT ID:** NCT07417501
- **Lead sponsor:** Tongji Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-03-01
- **Primary completion:** 2028-03-01
- **Final completion:** 2029-03-01
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-02-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07417501

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07417501, "Lenvatinib Plus PD-1 Inhibitor for Advanced Solid Tumors With 11q13 Amplification". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07417501. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*